Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Aligos Therapeutics Inc increased its cash reserves by 66.67%, or 54.31m. Cash Flow from Financing totalled 88.33m or 568.79% of revenues. In addition the company used 79.00m for operations while cash from investing totalled 44.98m.
Cash flow per share | -17.70 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 10.70 |
---|---|
Tangible book value per share | 10.70 |
More ▼
Balance sheet in USDView more
Current ratio | 4.23 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0031 |
---|---|
Total debt/total capital | 0.0031 |
More ▼